Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America.
Identifieur interne : 000197 ( PubMed/Curation ); précédent : 000196; suivant : 000198Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America.
Auteurs : John L. Goudreau [États-Unis] ; Adriana Pérez [États-Unis] ; Michael J. Aminoff [États-Unis] ; James T. Boyd [États-Unis] ; Keith D. Burau [États-Unis] ; Chadwick W. Christine [États-Unis] ; Maureen Leehey [États-Unis] ; John C. Morgan [États-Unis]Source :
- Journal of the neurological sciences [ 1878-5883 ] ; 2016.
English descriptors
- KwdEn :
- Age Factors, Aged, Antiparkinson Agents (therapeutic use), Canada (epidemiology), Choice Behavior, Dopamine Agents (therapeutic use), Educational Status, Female, Humans, Logistic Models, Male, Middle Aged, Monoamine Oxidase Inhibitors (therapeutic use), Multivariate Analysis, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Patient Acceptance of Health Care (statistics & numerical data), Time Factors, Treatment Outcome, United States (epidemiology).
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agents, Monoamine Oxidase Inhibitors.
- drug therapy : Parkinson Disease.
- epidemiology : Canada, Parkinson Disease, United States.
- statistics & numerical data : Patient Acceptance of Health Care.
- Age Factors, Aged, Choice Behavior, Educational Status, Female, Humans, Logistic Models, Male, Middle Aged, Multivariate Analysis, Time Factors, Treatment Outcome.
Abstract
The choice of dopaminergic therapy in early Parkinson disease (PD) is an important clinical decision, yet factors influencing this decision have not been extensively studied. We sought to investigate the factors that may be associated with the choice of dopaminergic therapy at the NINDS Exploratory Trials in PD (NET-PD) Long-Term Study-1 (LS1). NET-PD LS1 was a clinical trial of creatine versus placebo in participants with early, mild PD on stable doses of dopaminergic therapy. Baseline data from 1616 out of the 1741 participants were evaluated using univariable and multivariable logistic or generalized logit regression analyses for available factors associated with the choice of dopaminergic therapy. The dopaminergic therapy choice was determined as: (i) therapy that subjects recalled taking 180days before the study; (ii) therapy at baseline; and (iii) the longest duration of therapy reported by participants. Younger age, higher education level, longer length of time since PD diagnosis and use of an adjunctive, non-dopaminergic or monoamine oxidase inhibitor medication were associated with more frequent use of dopamine agonist compared to levodopa or combination therapy.
DOI: 10.1016/j.jns.2016.04.021
PubMed: 27288780
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000197
Links to Exploration step
pubmed:27288780Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America.</title><author><name sortKey="Goudreau, John L" sort="Goudreau, John L" uniqKey="Goudreau J" first="John L" last="Goudreau">John L. Goudreau</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Michigan State University, 804 Service Rd Room A217, East Lansing, MI 48824, USA. Electronic address: john.goudreau@hc.msu.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Michigan State University, 804 Service Rd Room A217, East Lansing, MI 48824</wicri:regionArea></affiliation></author><author><name sortKey="Perez, Adriana" sort="Perez, Adriana" uniqKey="Perez A" first="Adriana" last="Pérez">Adriana Pérez</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biostatistics, The University of Texas Health Science Center at Houston, UTHealth, USA. Electronic address: adriana.perez@uth.tmc.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics, The University of Texas Health Science Center at Houston, UTHealth</wicri:regionArea></affiliation></author><author><name sortKey="Aminoff, Michael J" sort="Aminoff, Michael J" uniqKey="Aminoff M" first="Michael J" last="Aminoff">Michael J. Aminoff</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of California San Francisco, 505 Parnassus Ave, Moffitt, San Francisco, CA 94143, USA. Electronic address: Michael.Aminoff@ucsf.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of California San Francisco, 505 Parnassus Ave, Moffitt, San Francisco, CA 94143</wicri:regionArea></affiliation></author><author><name sortKey="Boyd, James T" sort="Boyd, James T" uniqKey="Boyd J" first="James T" last="Boyd">James T. Boyd</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurological Sciences, University of Vermont, College of Medicine, 1 So. Prospect Street, UHC - Arnold 2, Burlington, VT 05401, USA. Electronic address: James.Boyd@uvm.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, University of Vermont, College of Medicine, 1 So. Prospect Street, UHC - Arnold 2, Burlington, VT 05401</wicri:regionArea></affiliation></author><author><name sortKey="Burau, Keith D" sort="Burau, Keith D" uniqKey="Burau K" first="Keith D" last="Burau">Keith D. Burau</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biostatistics, The University of Texas Health Science Center at Houston, UTHealth, USA. Electronic address: kb_athome@yahoo.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics, The University of Texas Health Science Center at Houston, UTHealth</wicri:regionArea></affiliation></author><author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W" last="Christine">Chadwick W. Christine</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of California San Francisco, 505 Parnassus Ave, Moffitt, San Francisco, CA 94143, USA. Electronic address: chad.christine@ucsf.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of California San Francisco, 505 Parnassus Ave, Moffitt, San Francisco, CA 94143</wicri:regionArea></affiliation></author><author><name sortKey="Leehey, Maureen" sort="Leehey, Maureen" uniqKey="Leehey M" first="Maureen" last="Leehey">Maureen Leehey</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Colorado, School of Medicine, Academic Office 1, Mail Stop B-185, 12631 East 17th Avenue, Aurora, CO 80045, USA. Electronic address: maureen.leehey@ucdenver.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Colorado, School of Medicine, Academic Office 1, Mail Stop B-185, 12631 East 17th Avenue, Aurora, CO 80045</wicri:regionArea></affiliation></author><author><name sortKey="Morgan, John C" sort="Morgan, John C" uniqKey="Morgan J" first="John C" last="Morgan">John C. Morgan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Georgia Regent's University, 1120 15th St, Augusta, GA 30912, USA. Electronic address: jmorgan@gru.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Georgia Regent's University, 1120 15th St, Augusta, GA 30912</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27288780</idno><idno type="pmid">27288780</idno><idno type="doi">10.1016/j.jns.2016.04.021</idno><idno type="wicri:Area/PubMed/Corpus">000197</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000197</idno><idno type="wicri:Area/PubMed/Curation">000197</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000197</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America.</title><author><name sortKey="Goudreau, John L" sort="Goudreau, John L" uniqKey="Goudreau J" first="John L" last="Goudreau">John L. Goudreau</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Michigan State University, 804 Service Rd Room A217, East Lansing, MI 48824, USA. Electronic address: john.goudreau@hc.msu.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Michigan State University, 804 Service Rd Room A217, East Lansing, MI 48824</wicri:regionArea></affiliation></author><author><name sortKey="Perez, Adriana" sort="Perez, Adriana" uniqKey="Perez A" first="Adriana" last="Pérez">Adriana Pérez</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biostatistics, The University of Texas Health Science Center at Houston, UTHealth, USA. Electronic address: adriana.perez@uth.tmc.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics, The University of Texas Health Science Center at Houston, UTHealth</wicri:regionArea></affiliation></author><author><name sortKey="Aminoff, Michael J" sort="Aminoff, Michael J" uniqKey="Aminoff M" first="Michael J" last="Aminoff">Michael J. Aminoff</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of California San Francisco, 505 Parnassus Ave, Moffitt, San Francisco, CA 94143, USA. Electronic address: Michael.Aminoff@ucsf.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of California San Francisco, 505 Parnassus Ave, Moffitt, San Francisco, CA 94143</wicri:regionArea></affiliation></author><author><name sortKey="Boyd, James T" sort="Boyd, James T" uniqKey="Boyd J" first="James T" last="Boyd">James T. Boyd</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurological Sciences, University of Vermont, College of Medicine, 1 So. Prospect Street, UHC - Arnold 2, Burlington, VT 05401, USA. Electronic address: James.Boyd@uvm.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, University of Vermont, College of Medicine, 1 So. Prospect Street, UHC - Arnold 2, Burlington, VT 05401</wicri:regionArea></affiliation></author><author><name sortKey="Burau, Keith D" sort="Burau, Keith D" uniqKey="Burau K" first="Keith D" last="Burau">Keith D. Burau</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biostatistics, The University of Texas Health Science Center at Houston, UTHealth, USA. Electronic address: kb_athome@yahoo.com.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Biostatistics, The University of Texas Health Science Center at Houston, UTHealth</wicri:regionArea></affiliation></author><author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W" last="Christine">Chadwick W. Christine</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of California San Francisco, 505 Parnassus Ave, Moffitt, San Francisco, CA 94143, USA. Electronic address: chad.christine@ucsf.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of California San Francisco, 505 Parnassus Ave, Moffitt, San Francisco, CA 94143</wicri:regionArea></affiliation></author><author><name sortKey="Leehey, Maureen" sort="Leehey, Maureen" uniqKey="Leehey M" first="Maureen" last="Leehey">Maureen Leehey</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Colorado, School of Medicine, Academic Office 1, Mail Stop B-185, 12631 East 17th Avenue, Aurora, CO 80045, USA. Electronic address: maureen.leehey@ucdenver.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Colorado, School of Medicine, Academic Office 1, Mail Stop B-185, 12631 East 17th Avenue, Aurora, CO 80045</wicri:regionArea></affiliation></author><author><name sortKey="Morgan, John C" sort="Morgan, John C" uniqKey="Morgan J" first="John C" last="Morgan">John C. Morgan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Georgia Regent's University, 1120 15th St, Augusta, GA 30912, USA. Electronic address: jmorgan@gru.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Georgia Regent's University, 1120 15th St, Augusta, GA 30912</wicri:regionArea></affiliation></author></analytic><series><title level="j">Journal of the neurological sciences</title><idno type="eISSN">1878-5883</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Canada (epidemiology)</term><term>Choice Behavior</term><term>Dopamine Agents (therapeutic use)</term><term>Educational Status</term><term>Female</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Monoamine Oxidase Inhibitors (therapeutic use)</term><term>Multivariate Analysis</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Patient Acceptance of Health Care (statistics & numerical data)</term><term>Time Factors</term><term>Treatment Outcome</term><term>United States (epidemiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agents</term><term>Monoamine Oxidase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Canada</term><term>Parkinson Disease</term><term>United States</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Patient Acceptance of Health Care</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Aged</term><term>Choice Behavior</term><term>Educational Status</term><term>Female</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Multivariate Analysis</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The choice of dopaminergic therapy in early Parkinson disease (PD) is an important clinical decision, yet factors influencing this decision have not been extensively studied. We sought to investigate the factors that may be associated with the choice of dopaminergic therapy at the NINDS Exploratory Trials in PD (NET-PD) Long-Term Study-1 (LS1). NET-PD LS1 was a clinical trial of creatine versus placebo in participants with early, mild PD on stable doses of dopaminergic therapy. Baseline data from 1616 out of the 1741 participants were evaluated using univariable and multivariable logistic or generalized logit regression analyses for available factors associated with the choice of dopaminergic therapy. The dopaminergic therapy choice was determined as: (i) therapy that subjects recalled taking 180days before the study; (ii) therapy at baseline; and (iii) the longest duration of therapy reported by participants. Younger age, higher education level, longer length of time since PD diagnosis and use of an adjunctive, non-dopaminergic or monoamine oxidase inhibitor medication were associated with more frequent use of dopamine agonist compared to levodopa or combination therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27288780</PMID><DateCreated><Year>2016</Year><Month>06</Month><Day>12</Day></DateCreated><DateCompleted><Year>2017</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2017</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5883</ISSN><JournalIssue CitedMedium="Internet"><Volume>366</Volume><PubDate><Year>2016</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of the neurological sciences</Title><ISOAbbreviation>J. Neurol. Sci.</ISOAbbreviation></Journal><ArticleTitle>Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America.</ArticleTitle><Pagination><MedlinePgn>74-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jns.2016.04.021</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-510X(16)30215-5</ELocationID><Abstract><AbstractText>The choice of dopaminergic therapy in early Parkinson disease (PD) is an important clinical decision, yet factors influencing this decision have not been extensively studied. We sought to investigate the factors that may be associated with the choice of dopaminergic therapy at the NINDS Exploratory Trials in PD (NET-PD) Long-Term Study-1 (LS1). NET-PD LS1 was a clinical trial of creatine versus placebo in participants with early, mild PD on stable doses of dopaminergic therapy. Baseline data from 1616 out of the 1741 participants were evaluated using univariable and multivariable logistic or generalized logit regression analyses for available factors associated with the choice of dopaminergic therapy. The dopaminergic therapy choice was determined as: (i) therapy that subjects recalled taking 180days before the study; (ii) therapy at baseline; and (iii) the longest duration of therapy reported by participants. Younger age, higher education level, longer length of time since PD diagnosis and use of an adjunctive, non-dopaminergic or monoamine oxidase inhibitor medication were associated with more frequent use of dopamine agonist compared to levodopa or combination therapy.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goudreau</LastName><ForeName>John L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Michigan State University, 804 Service Rd Room A217, East Lansing, MI 48824, USA. Electronic address: john.goudreau@hc.msu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, The University of Texas Health Science Center at Houston, UTHealth, USA. Electronic address: adriana.perez@uth.tmc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aminoff</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, 505 Parnassus Ave, Moffitt, San Francisco, CA 94143, USA. Electronic address: Michael.Aminoff@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>James T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, University of Vermont, College of Medicine, 1 So. Prospect Street, UHC - Arnold 2, Burlington, VT 05401, USA. Electronic address: James.Boyd@uvm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burau</LastName><ForeName>Keith D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, The University of Texas Health Science Center at Houston, UTHealth, USA. Electronic address: kb_athome@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christine</LastName><ForeName>Chadwick W</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, 505 Parnassus Ave, Moffitt, San Francisco, CA 94143, USA. Electronic address: chad.christine@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leehey</LastName><ForeName>Maureen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Colorado, School of Medicine, Academic Office 1, Mail Stop B-185, 12631 East 17th Avenue, Aurora, CO 80045, USA. Electronic address: maureen.leehey@ucdenver.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Georgia Regent's University, 1120 15th St, Augusta, GA 30912, USA. Electronic address: jmorgan@gru.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NET-PD Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neurol Sci</MedlineTA><NlmUniqueID>0375403</NlmUniqueID><ISSNLinking>0022-510X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002755" MajorTopicYN="Y">Choice Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008996" MajorTopicYN="N">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Clinical trial</Keyword><Keyword MajorTopicYN="Y">Dopamine agonists</Keyword><Keyword MajorTopicYN="Y">Levodopa</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>01</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>04</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27288780</ArticleId><ArticleId IdType="pii">S0022-510X(16)30215-5</ArticleId><ArticleId IdType="doi">10.1016/j.jns.2016.04.021</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000197 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000197 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:27288780
|texte= Choice of dopaminergic therapy among early, mild Parkinson disease subjects in North America.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:27288780" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |